Angiotensin Ⅱ Activates MCP-1 and Induces Cardiac Hypertrophy and Dysfunction via Toll-like Receptor 4

Aim: Angiotensin Ⅱ(Ang Ⅱ) produces reactive oxygen species (ROS), thus contributing to the development of cardiac hypertrophy and subsequent heart failure, and stimulates the expression of monocyte chemoattractant protein-1 (MCP-1). In addition, Toll-like receptor 4 (TLR4) is involved in the upregul...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of Atherosclerosis and Thrombosis 2015/08/26, Vol.22(8), pp.833-844
Hauptverfasser: Matsuda, Susumu, Umemoto, Seiji, Yoshimura, Koichi, Itoh, Shinichi, Murata, Tomoaki, Fukai, Tohru, Matsuzaki, Masunori
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 844
container_issue 8
container_start_page 833
container_title Journal of Atherosclerosis and Thrombosis
container_volume 22
creator Matsuda, Susumu
Umemoto, Seiji
Yoshimura, Koichi
Itoh, Shinichi
Murata, Tomoaki
Fukai, Tohru
Matsuzaki, Masunori
description Aim: Angiotensin Ⅱ(Ang Ⅱ) produces reactive oxygen species (ROS), thus contributing to the development of cardiac hypertrophy and subsequent heart failure, and stimulates the expression of monocyte chemoattractant protein-1 (MCP-1). In addition, Toll-like receptor 4 (TLR4) is involved in the upregulation of MCP-1. In order to clarify whether TLR4 is involved in the onset of cardiac dysfunction caused by Ang Ⅱ stimulation, we investigated the effects of TLR4 on oxidative stress, the MCP-1 expression and cardiac dysfunction in mice with Ang Ⅱ-induced hypertension. Methods: TLR4-deficient (Tlr4lps-d) and wild-type (WT) mice were randomized into groups treated with Ang Ⅱ, norepinephrine (NE) or a subdepressor dose of the Ang Ⅱreceptor blocker irbesartan (IRB) and Ang Ⅱ for two weeks. Results: Ang Ⅱ and NE similarly increased systolic blood pressure in all drug-treated groups compared to that observed in the control group among both WT and Tlr4lps-d mice (p<0.05). In the WT mice, Ang Ⅱ induced cardiac hypertrophy as well as vascular remodeling and perivascular fibrosis of the intramyocardial arteries and monocyte/macrophage infiltration in the heart (p<0.05). Furthermore, Ang Ⅱ treatment decreased the left ventricular diastolic function and resulted in a greater left ventricular end-systolic dimension (p<0.05) in addition to producing a five-fold increase in the NADPH oxidase activity, ROS content and MCP-1 expression (p<0.05). In contrast, the Tlr4lps-d mice showed little effects of Ang Ⅱ on these indices. In the WT mice, IRB treatment reversed these changes compared to that seen in the mice treated with Ang Ⅱ alone. NE produced little effect on any of the indices in either the WT or Tlr4lps-d mice. Conclusions: TLR4 may be involved in the processes underlying the increased oxidative stress, selectively activated MCP-1 expression and cardiac hypertrophy and dysfunction seen in cases of Ang Ⅱ- induced hypertension.
doi_str_mv 10.5551/jat.27292
format Article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5509415</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1708164272</sourcerecordid><originalsourceid>FETCH-LOGICAL-c6012-1f4b99a15e9e9e1561cf0ae359078dbfd4da4b093809fdf7edd87b6914bcdd623</originalsourceid><addsrcrecordid>eNpVUduO0zAUjBCIXRYe-AHkR3jI4mvivICqArsrLQKh5dly7JPWJbWLnVTkA_gQfo0vwW2WCmTp-MgznjM6UxTPCb4UQpDXGz1c0po29EFxTqTEJZM1e5h7xnPPa3lWPElpgzFjQtDHxRkVtaCsYufFeuFXLgzgk_Po989faGEGt9cDJPRx-bkkSHuLbrwdTX5Z6midNuh62kEcYtitpyP-bkrd6PPH4NHeaXQX-r7s3TdAX8DAbggR8afFo073CZ7d3xfF1w_v75bX5e2nq5vl4rY0FSa0JB1vm0YTAU0-RFTEdFgDEw2upW07y63mLW6YxE1nuxqslXVbNYS3xtqKsovizay7G9stWAN-iLpXu-i2Ok4qaKf-R7xbq1XYKyFww4nIAi_vBWL4PkIa1NYlA32vPYQxKVJjSSqe952pr2aqiSGlCN1pDMHqkIzKyahjMpn74l9fJ-bfKDLhaiZk1BndB987D2oTxujzwhT8qG3YTlpRTITCmFIsFc6DsGQsF86pZFzyg9LbWWmTBr2C0ygdB2d6mE1RJQ_laO6EmLWOCjz7A_TzuM4</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1708164272</pqid></control><display><type>article</type><title>Angiotensin Ⅱ Activates MCP-1 and Induces Cardiac Hypertrophy and Dysfunction via Toll-like Receptor 4</title><source>J-STAGE Free</source><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><creator>Matsuda, Susumu ; Umemoto, Seiji ; Yoshimura, Koichi ; Itoh, Shinichi ; Murata, Tomoaki ; Fukai, Tohru ; Matsuzaki, Masunori</creator><creatorcontrib>Matsuda, Susumu ; Umemoto, Seiji ; Yoshimura, Koichi ; Itoh, Shinichi ; Murata, Tomoaki ; Fukai, Tohru ; Matsuzaki, Masunori ; Yamaguchi University ; Institute of Experimental Animals ; Center for Clinical Research ; Department of Medicine and Clinical Science ; Yamaguchi University Hospital ; Yamaguchi University Graduate School of Medicine ; Departments of Medicine (Section of Cardiology and Pharmacology ; Department of Surgery and Clinical Science ; Center for Cardiovascular Research ; University of Illinois at Chicago ; Science Research Center</creatorcontrib><description>Aim: Angiotensin Ⅱ(Ang Ⅱ) produces reactive oxygen species (ROS), thus contributing to the development of cardiac hypertrophy and subsequent heart failure, and stimulates the expression of monocyte chemoattractant protein-1 (MCP-1). In addition, Toll-like receptor 4 (TLR4) is involved in the upregulation of MCP-1. In order to clarify whether TLR4 is involved in the onset of cardiac dysfunction caused by Ang Ⅱ stimulation, we investigated the effects of TLR4 on oxidative stress, the MCP-1 expression and cardiac dysfunction in mice with Ang Ⅱ-induced hypertension. Methods: TLR4-deficient (Tlr4lps-d) and wild-type (WT) mice were randomized into groups treated with Ang Ⅱ, norepinephrine (NE) or a subdepressor dose of the Ang Ⅱreceptor blocker irbesartan (IRB) and Ang Ⅱ for two weeks. Results: Ang Ⅱ and NE similarly increased systolic blood pressure in all drug-treated groups compared to that observed in the control group among both WT and Tlr4lps-d mice (p<0.05). In the WT mice, Ang Ⅱ induced cardiac hypertrophy as well as vascular remodeling and perivascular fibrosis of the intramyocardial arteries and monocyte/macrophage infiltration in the heart (p<0.05). Furthermore, Ang Ⅱ treatment decreased the left ventricular diastolic function and resulted in a greater left ventricular end-systolic dimension (p<0.05) in addition to producing a five-fold increase in the NADPH oxidase activity, ROS content and MCP-1 expression (p<0.05). In contrast, the Tlr4lps-d mice showed little effects of Ang Ⅱ on these indices. In the WT mice, IRB treatment reversed these changes compared to that seen in the mice treated with Ang Ⅱ alone. NE produced little effect on any of the indices in either the WT or Tlr4lps-d mice. Conclusions: TLR4 may be involved in the processes underlying the increased oxidative stress, selectively activated MCP-1 expression and cardiac hypertrophy and dysfunction seen in cases of Ang Ⅱ- induced hypertension.</description><identifier>ISSN: 1340-3478</identifier><identifier>EISSN: 1880-3873</identifier><identifier>DOI: 10.5551/jat.27292</identifier><identifier>PMID: 25752363</identifier><language>eng</language><publisher>Japan: Japan Atherosclerosis Society</publisher><subject>Adrenergic alpha-Agonists - pharmacology ; Angiotensin ; Angiotensin II - pharmacology ; Angiotensin II Type 1 Receptor Blockers - pharmacology ; Animals ; Biphenyl Compounds - pharmacology ; Cardiac hypertrophy ; Cardiomegaly - etiology ; Chemokine CCL2 - physiology ; Hypertension ; Hypertension - etiology ; Male ; Mice ; Mice, Inbred BALB C ; Monocyte chemoattractant protein-1 ; Mouse ; Norepinephrine - pharmacology ; Oxidative Stress - physiology ; Tetrazoles - pharmacology ; Toll-like receptor 4 ; Toll-Like Receptor 4 - physiology ; Vasoconstrictor Agents - pharmacology</subject><ispartof>Journal of Atherosclerosis and Thrombosis, 2015/08/26, Vol.22(8), pp.833-844</ispartof><rights>2015 Japan Atherosclerosis Society</rights><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c6012-1f4b99a15e9e9e1561cf0ae359078dbfd4da4b093809fdf7edd87b6914bcdd623</citedby><cites>FETCH-LOGICAL-c6012-1f4b99a15e9e9e1561cf0ae359078dbfd4da4b093809fdf7edd87b6914bcdd623</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,776,780,881,1877,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/25752363$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Matsuda, Susumu</creatorcontrib><creatorcontrib>Umemoto, Seiji</creatorcontrib><creatorcontrib>Yoshimura, Koichi</creatorcontrib><creatorcontrib>Itoh, Shinichi</creatorcontrib><creatorcontrib>Murata, Tomoaki</creatorcontrib><creatorcontrib>Fukai, Tohru</creatorcontrib><creatorcontrib>Matsuzaki, Masunori</creatorcontrib><creatorcontrib>Yamaguchi University</creatorcontrib><creatorcontrib>Institute of Experimental Animals</creatorcontrib><creatorcontrib>Center for Clinical Research</creatorcontrib><creatorcontrib>Department of Medicine and Clinical Science</creatorcontrib><creatorcontrib>Yamaguchi University Hospital</creatorcontrib><creatorcontrib>Yamaguchi University Graduate School of Medicine</creatorcontrib><creatorcontrib>Departments of Medicine (Section of Cardiology and Pharmacology</creatorcontrib><creatorcontrib>Department of Surgery and Clinical Science</creatorcontrib><creatorcontrib>Center for Cardiovascular Research</creatorcontrib><creatorcontrib>University of Illinois at Chicago</creatorcontrib><creatorcontrib>Science Research Center</creatorcontrib><title>Angiotensin Ⅱ Activates MCP-1 and Induces Cardiac Hypertrophy and Dysfunction via Toll-like Receptor 4</title><title>Journal of Atherosclerosis and Thrombosis</title><addtitle>JAT</addtitle><description>Aim: Angiotensin Ⅱ(Ang Ⅱ) produces reactive oxygen species (ROS), thus contributing to the development of cardiac hypertrophy and subsequent heart failure, and stimulates the expression of monocyte chemoattractant protein-1 (MCP-1). In addition, Toll-like receptor 4 (TLR4) is involved in the upregulation of MCP-1. In order to clarify whether TLR4 is involved in the onset of cardiac dysfunction caused by Ang Ⅱ stimulation, we investigated the effects of TLR4 on oxidative stress, the MCP-1 expression and cardiac dysfunction in mice with Ang Ⅱ-induced hypertension. Methods: TLR4-deficient (Tlr4lps-d) and wild-type (WT) mice were randomized into groups treated with Ang Ⅱ, norepinephrine (NE) or a subdepressor dose of the Ang Ⅱreceptor blocker irbesartan (IRB) and Ang Ⅱ for two weeks. Results: Ang Ⅱ and NE similarly increased systolic blood pressure in all drug-treated groups compared to that observed in the control group among both WT and Tlr4lps-d mice (p<0.05). In the WT mice, Ang Ⅱ induced cardiac hypertrophy as well as vascular remodeling and perivascular fibrosis of the intramyocardial arteries and monocyte/macrophage infiltration in the heart (p<0.05). Furthermore, Ang Ⅱ treatment decreased the left ventricular diastolic function and resulted in a greater left ventricular end-systolic dimension (p<0.05) in addition to producing a five-fold increase in the NADPH oxidase activity, ROS content and MCP-1 expression (p<0.05). In contrast, the Tlr4lps-d mice showed little effects of Ang Ⅱ on these indices. In the WT mice, IRB treatment reversed these changes compared to that seen in the mice treated with Ang Ⅱ alone. NE produced little effect on any of the indices in either the WT or Tlr4lps-d mice. Conclusions: TLR4 may be involved in the processes underlying the increased oxidative stress, selectively activated MCP-1 expression and cardiac hypertrophy and dysfunction seen in cases of Ang Ⅱ- induced hypertension.</description><subject>Adrenergic alpha-Agonists - pharmacology</subject><subject>Angiotensin</subject><subject>Angiotensin II - pharmacology</subject><subject>Angiotensin II Type 1 Receptor Blockers - pharmacology</subject><subject>Animals</subject><subject>Biphenyl Compounds - pharmacology</subject><subject>Cardiac hypertrophy</subject><subject>Cardiomegaly - etiology</subject><subject>Chemokine CCL2 - physiology</subject><subject>Hypertension</subject><subject>Hypertension - etiology</subject><subject>Male</subject><subject>Mice</subject><subject>Mice, Inbred BALB C</subject><subject>Monocyte chemoattractant protein-1</subject><subject>Mouse</subject><subject>Norepinephrine - pharmacology</subject><subject>Oxidative Stress - physiology</subject><subject>Tetrazoles - pharmacology</subject><subject>Toll-like receptor 4</subject><subject>Toll-Like Receptor 4 - physiology</subject><subject>Vasoconstrictor Agents - pharmacology</subject><issn>1340-3478</issn><issn>1880-3873</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2015</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpVUduO0zAUjBCIXRYe-AHkR3jI4mvivICqArsrLQKh5dly7JPWJbWLnVTkA_gQfo0vwW2WCmTp-MgznjM6UxTPCb4UQpDXGz1c0po29EFxTqTEJZM1e5h7xnPPa3lWPElpgzFjQtDHxRkVtaCsYufFeuFXLgzgk_Po989faGEGt9cDJPRx-bkkSHuLbrwdTX5Z6midNuh62kEcYtitpyP-bkrd6PPH4NHeaXQX-r7s3TdAX8DAbggR8afFo073CZ7d3xfF1w_v75bX5e2nq5vl4rY0FSa0JB1vm0YTAU0-RFTEdFgDEw2upW07y63mLW6YxE1nuxqslXVbNYS3xtqKsovizay7G9stWAN-iLpXu-i2Ok4qaKf-R7xbq1XYKyFww4nIAi_vBWL4PkIa1NYlA32vPYQxKVJjSSqe952pr2aqiSGlCN1pDMHqkIzKyahjMpn74l9fJ-bfKDLhaiZk1BndB987D2oTxujzwhT8qG3YTlpRTITCmFIsFc6DsGQsF86pZFzyg9LbWWmTBr2C0ygdB2d6mE1RJQ_laO6EmLWOCjz7A_TzuM4</recordid><startdate>20150826</startdate><enddate>20150826</enddate><creator>Matsuda, Susumu</creator><creator>Umemoto, Seiji</creator><creator>Yoshimura, Koichi</creator><creator>Itoh, Shinichi</creator><creator>Murata, Tomoaki</creator><creator>Fukai, Tohru</creator><creator>Matsuzaki, Masunori</creator><general>Japan Atherosclerosis Society</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20150826</creationdate><title>Angiotensin Ⅱ Activates MCP-1 and Induces Cardiac Hypertrophy and Dysfunction via Toll-like Receptor 4</title><author>Matsuda, Susumu ; Umemoto, Seiji ; Yoshimura, Koichi ; Itoh, Shinichi ; Murata, Tomoaki ; Fukai, Tohru ; Matsuzaki, Masunori</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c6012-1f4b99a15e9e9e1561cf0ae359078dbfd4da4b093809fdf7edd87b6914bcdd623</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2015</creationdate><topic>Adrenergic alpha-Agonists - pharmacology</topic><topic>Angiotensin</topic><topic>Angiotensin II - pharmacology</topic><topic>Angiotensin II Type 1 Receptor Blockers - pharmacology</topic><topic>Animals</topic><topic>Biphenyl Compounds - pharmacology</topic><topic>Cardiac hypertrophy</topic><topic>Cardiomegaly - etiology</topic><topic>Chemokine CCL2 - physiology</topic><topic>Hypertension</topic><topic>Hypertension - etiology</topic><topic>Male</topic><topic>Mice</topic><topic>Mice, Inbred BALB C</topic><topic>Monocyte chemoattractant protein-1</topic><topic>Mouse</topic><topic>Norepinephrine - pharmacology</topic><topic>Oxidative Stress - physiology</topic><topic>Tetrazoles - pharmacology</topic><topic>Toll-like receptor 4</topic><topic>Toll-Like Receptor 4 - physiology</topic><topic>Vasoconstrictor Agents - pharmacology</topic><toplevel>online_resources</toplevel><creatorcontrib>Matsuda, Susumu</creatorcontrib><creatorcontrib>Umemoto, Seiji</creatorcontrib><creatorcontrib>Yoshimura, Koichi</creatorcontrib><creatorcontrib>Itoh, Shinichi</creatorcontrib><creatorcontrib>Murata, Tomoaki</creatorcontrib><creatorcontrib>Fukai, Tohru</creatorcontrib><creatorcontrib>Matsuzaki, Masunori</creatorcontrib><creatorcontrib>Yamaguchi University</creatorcontrib><creatorcontrib>Institute of Experimental Animals</creatorcontrib><creatorcontrib>Center for Clinical Research</creatorcontrib><creatorcontrib>Department of Medicine and Clinical Science</creatorcontrib><creatorcontrib>Yamaguchi University Hospital</creatorcontrib><creatorcontrib>Yamaguchi University Graduate School of Medicine</creatorcontrib><creatorcontrib>Departments of Medicine (Section of Cardiology and Pharmacology</creatorcontrib><creatorcontrib>Department of Surgery and Clinical Science</creatorcontrib><creatorcontrib>Center for Cardiovascular Research</creatorcontrib><creatorcontrib>University of Illinois at Chicago</creatorcontrib><creatorcontrib>Science Research Center</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Journal of Atherosclerosis and Thrombosis</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Matsuda, Susumu</au><au>Umemoto, Seiji</au><au>Yoshimura, Koichi</au><au>Itoh, Shinichi</au><au>Murata, Tomoaki</au><au>Fukai, Tohru</au><au>Matsuzaki, Masunori</au><aucorp>Yamaguchi University</aucorp><aucorp>Institute of Experimental Animals</aucorp><aucorp>Center for Clinical Research</aucorp><aucorp>Department of Medicine and Clinical Science</aucorp><aucorp>Yamaguchi University Hospital</aucorp><aucorp>Yamaguchi University Graduate School of Medicine</aucorp><aucorp>Departments of Medicine (Section of Cardiology and Pharmacology</aucorp><aucorp>Department of Surgery and Clinical Science</aucorp><aucorp>Center for Cardiovascular Research</aucorp><aucorp>University of Illinois at Chicago</aucorp><aucorp>Science Research Center</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Angiotensin Ⅱ Activates MCP-1 and Induces Cardiac Hypertrophy and Dysfunction via Toll-like Receptor 4</atitle><jtitle>Journal of Atherosclerosis and Thrombosis</jtitle><addtitle>JAT</addtitle><date>2015-08-26</date><risdate>2015</risdate><volume>22</volume><issue>8</issue><spage>833</spage><epage>844</epage><pages>833-844</pages><issn>1340-3478</issn><eissn>1880-3873</eissn><abstract>Aim: Angiotensin Ⅱ(Ang Ⅱ) produces reactive oxygen species (ROS), thus contributing to the development of cardiac hypertrophy and subsequent heart failure, and stimulates the expression of monocyte chemoattractant protein-1 (MCP-1). In addition, Toll-like receptor 4 (TLR4) is involved in the upregulation of MCP-1. In order to clarify whether TLR4 is involved in the onset of cardiac dysfunction caused by Ang Ⅱ stimulation, we investigated the effects of TLR4 on oxidative stress, the MCP-1 expression and cardiac dysfunction in mice with Ang Ⅱ-induced hypertension. Methods: TLR4-deficient (Tlr4lps-d) and wild-type (WT) mice were randomized into groups treated with Ang Ⅱ, norepinephrine (NE) or a subdepressor dose of the Ang Ⅱreceptor blocker irbesartan (IRB) and Ang Ⅱ for two weeks. Results: Ang Ⅱ and NE similarly increased systolic blood pressure in all drug-treated groups compared to that observed in the control group among both WT and Tlr4lps-d mice (p<0.05). In the WT mice, Ang Ⅱ induced cardiac hypertrophy as well as vascular remodeling and perivascular fibrosis of the intramyocardial arteries and monocyte/macrophage infiltration in the heart (p<0.05). Furthermore, Ang Ⅱ treatment decreased the left ventricular diastolic function and resulted in a greater left ventricular end-systolic dimension (p<0.05) in addition to producing a five-fold increase in the NADPH oxidase activity, ROS content and MCP-1 expression (p<0.05). In contrast, the Tlr4lps-d mice showed little effects of Ang Ⅱ on these indices. In the WT mice, IRB treatment reversed these changes compared to that seen in the mice treated with Ang Ⅱ alone. NE produced little effect on any of the indices in either the WT or Tlr4lps-d mice. Conclusions: TLR4 may be involved in the processes underlying the increased oxidative stress, selectively activated MCP-1 expression and cardiac hypertrophy and dysfunction seen in cases of Ang Ⅱ- induced hypertension.</abstract><cop>Japan</cop><pub>Japan Atherosclerosis Society</pub><pmid>25752363</pmid><doi>10.5551/jat.27292</doi><tpages>12</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1340-3478
ispartof Journal of Atherosclerosis and Thrombosis, 2015/08/26, Vol.22(8), pp.833-844
issn 1340-3478
1880-3873
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5509415
source J-STAGE Free; MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals
subjects Adrenergic alpha-Agonists - pharmacology
Angiotensin
Angiotensin II - pharmacology
Angiotensin II Type 1 Receptor Blockers - pharmacology
Animals
Biphenyl Compounds - pharmacology
Cardiac hypertrophy
Cardiomegaly - etiology
Chemokine CCL2 - physiology
Hypertension
Hypertension - etiology
Male
Mice
Mice, Inbred BALB C
Monocyte chemoattractant protein-1
Mouse
Norepinephrine - pharmacology
Oxidative Stress - physiology
Tetrazoles - pharmacology
Toll-like receptor 4
Toll-Like Receptor 4 - physiology
Vasoconstrictor Agents - pharmacology
title Angiotensin Ⅱ Activates MCP-1 and Induces Cardiac Hypertrophy and Dysfunction via Toll-like Receptor 4
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-30T22%3A34%3A45IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Angiotensin%20%E2%85%A1%20Activates%20MCP-1%20and%20Induces%20Cardiac%20Hypertrophy%20and%20Dysfunction%20via%20Toll-like%20Receptor%204&rft.jtitle=Journal%20of%20Atherosclerosis%20and%20Thrombosis&rft.au=Matsuda,%20Susumu&rft.aucorp=Yamaguchi%20University&rft.date=2015-08-26&rft.volume=22&rft.issue=8&rft.spage=833&rft.epage=844&rft.pages=833-844&rft.issn=1340-3478&rft.eissn=1880-3873&rft_id=info:doi/10.5551/jat.27292&rft_dat=%3Cproquest_pubme%3E1708164272%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1708164272&rft_id=info:pmid/25752363&rfr_iscdi=true